Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.
about
Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate CancerClinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancerComprehensive assessment for novel prostate cancer markers in the prostate-specific antigen era: focusing on Asians and Asian countriesProstate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal BiomarkersHow Precisely Can Prostate Cancer Be Managed?Clinical performance of the Prostate Health Index (PHI) for the prediction of prostate cancer in obese men: data from the PROMEtheuS project, a multicentre European prospective study.Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml-1.Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literatureProstate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/mlSerum markers in prostate cancer detectionThe prostate health index selectively identifies clinically significant prostate cancer.Urinary Volatile Organic Compounds for the Detection of Prostate CancerComparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.[-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first reportPSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer.The Prostate Health Index: Its Utility in Prostate Cancer DetectionMulticenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.The use of a gas chromatography-sensor system combined with advanced statistical methods, towards the diagnosis of urological malignancies.Performance of the Prostate Health Index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonographyProstate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)Biomarkers for prostate cancer: present challenges and future opportunities.The Prostate Health Index: a new test for the detection of prostate cancer.Prostate cancer antigen 3 moderately improves diagnostic accuracy in Chinese patients undergoing first prostate biopsy.An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis.Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis.Proteomics of human prostate cancer biospecimens: the global, systems-wide perspective for protein markers with potential clinical utility.Biomarkers in prostate cancer: new era and prospective.Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen.Point-of-care diagnostics, a major opportunity for change in traditional diagnostic approaches: potential and limitations.Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.Current biomarkers for diagnosing of prostate cancer.Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mLMalakoplakia of the Prostate as a Mimicker of Prostate Cancer on Prostate Health Index and Magnetic Resonance Imaging-Fusion Prostate Biopsy: A Case Report.Clinical Utility of Biomarkers in Localized Prostate Cancer.Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.Prostate transitional zone volume-based nomogram for predicting prostate cancer and high progression prostate cancer in a real-world population.PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER.Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China.Improving multivariable prostate cancer risk assessment using the Prostate Health Index.
P2860
Q26784517-3A6B7DBC-228B-4782-A8EC-F69A496F5665Q26824913-078DC6CF-5AE8-4002-894E-0A3537FE5071Q26996461-A9B4010A-EDA4-48F0-9188-1965428CC12DQ28075610-0FF86CC4-44CD-4687-B90E-214AA3049C0AQ28078942-9F9D77D1-A3A1-4AF5-B059-B70BA62BD571Q30843223-0C7D4900-712D-42FE-8F0A-20BEC710EFE7Q33668692-8022CB14-7041-47AF-BD04-DD924E3DA416Q33911725-BED176AC-B972-4818-8BA5-F9BE44AE1F4EQ34825819-29675E4E-6C3A-49FC-BE98-ADDDDAE81550Q35042519-72430378-4833-484D-954A-F46B4FA77913Q35498981-41878F53-03F3-4618-965D-FAE0A95EF7E8Q35849909-8C27B6EA-3341-40C7-B03E-B4663200D160Q35854594-EB7CE745-16A0-42BD-AE4B-061E59A6DE90Q35969948-A2ACA947-D712-4718-BD6F-B6C412338ACEQ35993261-21BA66AB-B635-4FD2-BD6F-82870177425AQ36328005-44B06075-1F4E-45A2-907D-47D47C1A1E24Q36416441-53BBC6FF-F893-4C97-AB57-37EF4BFE3196Q36926798-5B89B7B1-AD89-4859-B427-ED106A273CC0Q37113204-0FEB0DB5-F487-4519-80F7-F941BEB8CA96Q37155070-C7944B19-C95D-4EE2-969F-1C885B7DFB44Q37474443-B6050811-5271-4F34-A81E-F6A32914281CQ37619016-D7BE81B0-8236-4BFF-B864-D1B632F322DCQ37644685-FCC9B9B2-12AE-4CB7-B9F7-ED27DECEC1C9Q37691113-F6452F4F-1D17-49C7-9ACB-01FD2F0EAA3BQ37738370-B08B8521-DCD7-4C0C-A4EC-418461A8E497Q38132914-A8E1E272-10CF-47FB-890C-D6481A243EAFQ38232466-363B178C-0AD0-41E2-8A00-233B3519975AQ38241107-6E0809A5-D463-4586-9AC5-5B05AB2335DEQ38258595-9442788C-4900-4D57-813B-9260649A386AQ38546301-614BC531-5AF7-4404-89BF-3EB718EA1235Q38584370-AF76FA3C-48A4-4B51-BC2A-3B3818439932Q38631489-9371E040-CCD3-47A5-8FBB-E7EA002005E5Q38665504-38B058BF-5698-4FAC-8DB3-AD0C6F7FDBD9Q38792354-7928C05F-3B3D-4BF5-89B6-F2AE0E03C4A0Q38854599-ADEA6517-F98C-456B-AEEC-08F41C26B39FQ38874800-1C87C9A9-8E07-4524-A530-79B1EBD0B967Q38913913-2052D315-BC10-4580-A458-86FF691F8007Q39108592-4B15D8D2-6095-418C-ADFA-14BA38607D11Q40140207-F99B7CBB-7493-44EC-A928-CDE8C0ACC9DDQ40270088-7714AD18-1961-46E2-BBAF-03D7FB89C5EB
P2860
Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Serum isoform [-2]proPSA deriv ...... a multicentric European study.
@en
Serum isoform [-2]proPSA deriv ...... a multicentric European study.
@nl
type
label
Serum isoform [-2]proPSA deriv ...... a multicentric European study.
@en
Serum isoform [-2]proPSA deriv ...... a multicentric European study.
@nl
prefLabel
Serum isoform [-2]proPSA deriv ...... a multicentric European study.
@en
Serum isoform [-2]proPSA deriv ...... a multicentric European study.
@nl
P2093
P50
P1433
P1476
Serum isoform [-2]proPSA deriv ...... a multicentric European study
@en
P2093
Alexander Haese
Alexandre de la Taille
Amy Sussman
Joan Palou Redorta
Josep Alberola Bou
Markus Graefen
Massimo Freschi
Salvador Esquena Fernández
Vincenzo Scattoni
Vittorio Bini
P304
P356
10.1016/J.EURURO.2013.01.011
P407
P50
P577
2013-01-24T00:00:00Z